WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001030825) A NOVEL POLYPEPTIDE-HUMAN SPLICING FACTOR 25 AND THE POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2001/030825 International Application No.: PCT/CN2000/000387
Publication Date: 03.05.2001 International Filing Date: 27.10.2000
Chapter 2 Demand Filed: 21.05.2001
IPC:
A61K 38/00 (2006.01) ,C07K 14/47 (2006.01)
Applicants: MAO, Yumin[CN/CN]; CN (UsOnly)
XIE, Yi[CN/CN]; CN (UsOnly)
SHANGHAI BIO ROAD GENE DEVELOPMENT LTD.[CN/CN]; 12th Floor 3rd Building No. 1111, Zhongshan Bei Er Road Shanghai 200092, CN (AllExceptUS)
Inventors: MAO, Yumin; CN
XIE, Yi; CN
Agent: SHANGHAI HUA DONG PATENT AGENCY; 319 Yue Yang Road Shanghai 200031, CN
Priority Data:
99 1 19898.028.10.1999CN
Title (EN) A NOVEL POLYPEPTIDE-HUMAN SPLICING FACTOR 25 AND THE POLYNUCLEOTIDE ENCODING SAID POLYPEPTIDE
(FR) NOUVEAU POLYPEPTIDE, FACTEUR HUMAIN D'EPISSAGE 25, ET POLYNUCLEOTIDE CODANT POUR CE POLYPEPTIDE
Abstract:
(EN) The invention disclosed a new kind of polypeptide-human splicing factor 25 and the polynucleotide encoding said polypeptide and a process for producing the polypeptide by recombinant methods. It also disclosed the method of applying the polypeptide for the treatment of various kinds of diseases, such as cancer, hemopathy, HIV infection, immune diseases and inflammation. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said human splicing factor 25.
(FR) L'invention concerne un nouveau polypeptide, un facteur humain d'épissage 25, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour le facteur humain d'épissage 25.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)